LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) dropped 4.1% during trading on Tuesday . The stock traded as low as $28.84 and last traded at $28.84. Approximately 38,505 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 137,698 shares. The stock had previously closed at $30.07.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on LENZ shares. HC Wainwright reissued a "buy" rating and issued a $38.00 target price on shares of LENZ Therapeutics in a report on Thursday, November 7th. Raymond James started coverage on shares of LENZ Therapeutics in a report on Friday, September 27th. They issued an "outperform" rating and a $37.00 target price for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $35.40.
Check Out Our Latest Research Report on LENZ
LENZ Therapeutics Stock Performance
The stock's 50-day moving average is $32.39 and its two-hundred day moving average is $25.78.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter in the prior year, the company posted ($1.33) EPS. On average, analysts expect that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.
Hedge Funds Weigh In On LENZ Therapeutics
Several institutional investors have recently added to or reduced their stakes in LENZ. SG Americas Securities LLC bought a new position in shares of LENZ Therapeutics in the 3rd quarter valued at about $107,000. Squarepoint Ops LLC bought a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $181,000. MetLife Investment Management LLC purchased a new position in shares of LENZ Therapeutics in the 3rd quarter worth approximately $182,000. GSA Capital Partners LLP bought a new stake in shares of LENZ Therapeutics in the 3rd quarter worth about $246,000. Finally, Jane Street Group LLC purchased a new stake in LENZ Therapeutics in the 3rd quarter worth about $286,000. Hedge funds and other institutional investors own 54.32% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Articles
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
